Latest news and press releases about Novocure Ltd (NVCR): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
Price
| Price | $14.94 |
| Market Cap | $1.7B |
| Exchange | NASDAQ |
| Country | CH |
Valuation Ratios
| Price / Book | 5.08 |
| EV / EBITDA | -15.48 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -44.00% |
| Return on Invested Capital | -26.15% |
| Return on Assets | -18.68% |
| Gross Margin | 76.13% |
| Operating Margin | -22.08% |
| Net Margin | -21.25% |
Related companies: AZTA · BLFS · ESTA · EVO · KMTS · NEOG · PLSE
Explore sector: Healthcare · Medical - Devices
More sections of NVCR: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks